Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70039 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Yuji Kumagai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Kitasato University Hospital, Kanagawa, Japan. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Taiho Pharmaceutical Co., Ltd..
Abstract (Originalsprache)
Aim
TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Methods
Two phase 1 studies (single ascending‐dose [SAD] and multiple ascending‐dose [MAD]) assessed the pharmacokinetics (including effect of food), pharmacodynamics (Btk occupancy, inhibition of basophil activation) and safety of TAS5315 (up to 8 mg/day) in healthy males.
Results
TAS5315 showed linear pharmacokinetics over a 0.01‐8 mg dose range; maximum plasma concentration and area under the plasma concentration‐time curve were reduced by ~40% by food. TAS5315 had dose dependent effects on Btk and basophil activation. In the SAD study, doses ≥2 mg resulted in mean Btk occupancy of almost 100% at 2 and 6 h, and >80% at 24 h, post‐administration. TAS5315 1‐8 mg/day inhibited basophil activation (mean change from baseline −55% to −89%). TAS5315 was generally tolerable. Although it dose‐dependently reduced platelet aggregation (over 2‐8 mg in both studies) and prolonged bleeding time (1‐8 mg in the MAD study), no relationship between these effects and clinical symptoms was observed. All adverse drug reactions were mild and resolved without treatment; no noteworthy safety concerns were observed in either study.
Conclusion
These data indicate TAS5315 has potential as a novel therapeutic for immunological diseases associated with aberrant Btk signalling, including RA and CSU. Further evaluation of TAS5315 is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kitasato University Hospital, Kanagawa, Japan.
- Clinical Trial Center, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan.
- Department of Pharmacology and Toxicology, School of Medicine, Dokkyo Medical University, Tochigi, Japan.
- Laboratory of Clinical Pharmacoepidemiology and Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University, Kanagawa, Japan.
ORCID-Profile: Yuji Kumagai, Tomoe Fujita, Mika Maeda, Akiko Yamamoto, Hideki Amano
Förderung
- Taiho Pharmaceutical Co., Ltd.
Zitieren
APA
Kumagai, Y., Fujita, T., Maeda, M., Yamamoto, A., & Amano, H. (2025). Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70039
Vancouver
Kumagai Y, Fujita T, Maeda M, Yamamoto A, Amano H. Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70039
BibTeX
@article{Kumagai2025,
author = {Kumagai, Yuji and Fujita, Tomoe and Maeda, Mika and Yamamoto, Akiko and Amano, Hideki},
title = {Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70039}
}
EUVIMED